Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil

被引:0
|
作者
Koper, Agnieszka [1 ,2 ]
Wilenski, Slawomir [3 ,4 ]
Sledzinska, Paulina [5 ]
Bebyn, Marek [5 ]
Koper, Krzysztof [2 ,6 ]
机构
[1] Nicolaus Copernicus Univ Torun, Dept Oncol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[2] Franciszek Lukaszczyk Oncol Ctr, Dept Oncol, PL-85796 Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ Torun, Dept Pharmaceut Technol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[4] Hosp Pharm, F Lukaszczyk Oncol Ctr, Cent Cytostat Drug Dept, PL-85796 Bydgoszcz, Poland
[5] 10th Mil Res Hosp & Polyclin, PL-85681 Bydgoszcz, Poland
[6] Nicolaus Copernicus Univ Torun, Dept Clin Oncol & Nursing, Dept Oncol Surg, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
关键词
Chemotherapy; Colorectal cancer; Prognostic factors; Trifluridine/Tipiracil; TAS-102; MONOTHERAPY; PLUS BEVACIZUMAB; DOUBLE-BLIND; OPEN-LABEL; HYPERTENSION; SURVIVAL; THERAPY; REGORAFENIB; CETUXIMAB; TRIAL;
D O I
10.1007/s00432-023-04909-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. Methods We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. Results After starting Trifluridine/ Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47- 65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. Conclusion We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.y
引用
收藏
页码:10867 / 10877
页数:11
相关论文
共 50 条
  • [1] Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
    Agnieszka Koper
    Sławomir Wileński
    Paulina Śledzińska
    Marek Bebyn
    Krzysztof Koper
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 10867 - 10877
  • [2] Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
    Malik, Mateusz
    Michalak, Maciej
    Radecka, Barbara
    Gelej, Marek
    Jackowska, Aleksandra
    Filipczyk-Cisarz, Emilia
    Hetman, Katarzyna
    Foszczynska-Kloda, Malgorzata
    Kania-Zembaczynska, Beata
    Manka, Danuta
    Orlikowska, Marlena
    Rogowska-Dros, Hanna
    Bodnar, Lubomir
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [3] Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Yoshiaki Fujimoto
    Ryota Nakanishi
    Mamoru Nukatsuka
    Kazuaki Matsuoka
    Koji Ando
    Takeshi Wakasa
    Hiroyuki Kitao
    Eiji Oki
    Yoshihiko Maehara
    Masaki Mori
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 1029 - 1038
  • [4] Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Fujimoto, Yoshiaki
    Nakanishi, Ryota
    Nukatsuka, Mamoru
    Matsuoka, Kazuaki
    Ando, Koji
    Wakasa, Takeshi
    Kitao, Hiroyuki
    Oki, Eiji
    Maehara, Yoshihiko
    Mori, Masaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (06) : 1029 - 1038
  • [5] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Martinez-Lago, Nieves
    Calleja Chucla, Teresa
    Alonso De Castro, Beatriz
    Varela Ponte, Rafael
    Reboredo Rendo, Cristina
    Gomez-Randulfe Rodriguez, Martin Igor
    Silva Diaz, Sofia
    Grana Suarez, Begona
    de la Camara Gomez, Juan
    Busto Fernandez, Fernando
    Mateos Salvador, Maria
    Reboredo Lopez, Margarita
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [6] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Nieves Martínez-Lago
    Teresa Calleja Chucla
    Beatriz Alonso De Castro
    Rafael Varela Ponte
    Cristina Reboredo Rendo
    Martin Igor Gomez-Randulfe Rodriguez
    Sofia Silva Diaz
    Begoña Graña Suarez
    Juan de la Cámara Gomez
    Fernando Busto Fernández
    María Mateos Salvador
    Margarita Reboredo Lopez
    Scientific Reports, 12
  • [7] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe M.
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik P.
    Benhadji, Karim A.
    Amellal, Nadia
    Leger, Catherine
    Vidot, Loick
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
  • [8] Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil
    Skuja, Elina
    Gerina-Berzina, Aija
    Hegmane, Alinta
    Zvirbule, Zanete
    Vecvagare, Eva
    Purkalne, Gunta
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (05) : 699 - 702
  • [9] Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study
    Garcia-Alfonso, P.
    Reina Zoilo, J.
    Mata Velasco, E.
    Llanos, M.
    Illan Varella, A.
    Safont Aguilera, M.
    Delgado Urena, M.
    Castanon, C.
    Pimentel, P.
    Alonso Orduna, V.
    Mendez, J.
    Rivera Herrero, F.
    Siso, I.
    Rodriguez-Pascual, J.
    Gravalos Castro, C.
    Afonso, R.
    Fernandez Ranada, I.
    Grandez, R.
    Moreno, M.
    Munoz, A. Lopez
    Garcia-Paredes, B.
    Aranda, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S113 - S113
  • [10] Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
    Tasseau, Clara
    Gallois, Claire
    BULLETIN DU CANCER, 2024, 111 (12) : 1087 - 1088